154 related articles for article (PubMed ID: 23295918)
1. Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.
Salas V; Pastor FJ; Calvo E; Sutton DA; Fothergill AW; Guarro J
Antimicrob Agents Chemother; 2013 Mar; 57(3):1404-8. PubMed ID: 23295918
[TBL] [Abstract][Full Text] [Related]
2. MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex.
Salas V; Pastor FJ; Sutton DA; Calvo E; Mayayo E; Fothergill AW; Rinaldi MG; Guarro J
Antimicrob Agents Chemother; 2013 Mar; 57(3):1532-4. PubMed ID: 23295929
[TBL] [Abstract][Full Text] [Related]
3. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
Mavridou E; Bruggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2010 Nov; 54(11):4758-64. PubMed ID: 20733046
[TBL] [Abstract][Full Text] [Related]
4.
Colley T; Sehra G; Chowdhary A; Alanio A; Kelly SL; Kizawa Y; Armstrong-James D; Fisher MC; Warrilow AGS; Parker JE; Kelly DE; Kimura G; Nishimoto Y; Sunose M; Onions S; Crepin D; Lagasse F; Crittall M; Shannon J; McConville M; King-Underwood J; Naylor A; Bretagne S; Murray J; Ito K; Strong P; Rapeport G
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439966
[TBL] [Abstract][Full Text] [Related]
5. Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole.
Beernaert LA; Pasmans F; Van Waeyenberghe L; Dorrestein GM; Verstappen F; Vercammen F; Haesebrouck F; Martel A
Antimicrob Agents Chemother; 2009 May; 53(5):2199-201. PubMed ID: 19258265
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
7. Are epidemiologic cut-off values predictors of the in vivo efficacy of azoles in experimental aspergillosis?
Calvo E; Pastor FJ; Sutton DA; Fothergill AW; Rinaldi MG; Salas V; Guarro J
Diagn Microbiol Infect Dis; 2012 Oct; 74(2):158-65. PubMed ID: 22858549
[TBL] [Abstract][Full Text] [Related]
8. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.
Pfaller MA; Diekema DJ; Ghannoum MA; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Espinel-Ingroff A; Fowler CL; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Sheehan DJ; Walsh TJ;
J Clin Microbiol; 2009 Oct; 47(10):3142-6. PubMed ID: 19692559
[TBL] [Abstract][Full Text] [Related]
9. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.
Verweij PE; Te Dorsthorst DT; Rijs AJ; De Vries-Hospers HG; Meis JF
J Clin Microbiol; 2002 Jul; 40(7):2648-50. PubMed ID: 12089298
[TBL] [Abstract][Full Text] [Related]
10. Azole preexposure affects the Aspergillus fumigatus population in patients.
Alanio A; Cabaret O; Sitterlé E; Costa JM; Brisse S; Cordonnier C; Bretagne S
Antimicrob Agents Chemother; 2012 Sep; 56(9):4948-50. PubMed ID: 22710122
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Majithiya JB; Lass-Flörl C; Cuenca-Estrella M; Arendrup MC; Warn PA; Hope WW
J Infect Dis; 2012 Aug; 206(3):442-52. PubMed ID: 22634880
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazole.
Serrano MC; Morilla D; Valverde A; Chávez M; Espinel-Ingroff A; Claro R; Ramírez M; Mazuelos EM
J Clin Microbiol; 2003 Nov; 41(11):5270-2. PubMed ID: 14605181
[TBL] [Abstract][Full Text] [Related]
13.
Colley T; Alanio A; Kelly SL; Sehra G; Kizawa Y; Warrilow AGS; Parker JE; Kelly DE; Kimura G; Anderson-Dring L; Nakaoki T; Sunose M; Onions S; Crepin D; Lagasse F; Crittall M; Shannon J; Cooke M; Bretagne S; King-Underwood J; Murray J; Ito K; Strong P; Rapeport G
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223388
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis.
Meletiadis J; Mavridou E; Melchers WJ; Mouton JW; Verweij PE
Antimicrob Agents Chemother; 2012 May; 56(5):2524-9. PubMed ID: 22330922
[TBL] [Abstract][Full Text] [Related]
15. Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus.
Dannaoui E; Garcia-Hermoso D; Naccache JM; Meneau I; Sanglard D; Bouges-Michel C; Valeyre D; Lortholary O
J Med Microbiol; 2006 Oct; 55(Pt 10):1457-1459. PubMed ID: 17005798
[TBL] [Abstract][Full Text] [Related]
16. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.
Seyedmousavi S; Meletiadis J; Melchers WJ; Rijs AJ; Mouton JW; Verweij PE
Antimicrob Agents Chemother; 2013 Feb; 57(2):796-803. PubMed ID: 23183435
[TBL] [Abstract][Full Text] [Related]
17. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole.
Escribano P; Recio S; Peláez T; Bouza E; Guinea J
Antimicrob Agents Chemother; 2011 May; 55(5):2460-2. PubMed ID: 21321141
[TBL] [Abstract][Full Text] [Related]
18. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Warn PA; Hope WW
Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
[TBL] [Abstract][Full Text] [Related]
19. SREBP-dependent triazole susceptibility in Aspergillus fumigatus is mediated through direct transcriptional regulation of erg11A (cyp51A).
Blosser SJ; Cramer RA
Antimicrob Agents Chemother; 2012 Jan; 56(1):248-57. PubMed ID: 22006005
[TBL] [Abstract][Full Text] [Related]
20. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).
Espinel-Ingroff A; Diekema DJ; Fothergill A; Johnson E; Pelaez T; Pfaller MA; Rinaldi MG; Canton E; Turnidge J
J Clin Microbiol; 2010 Sep; 48(9):3251-7. PubMed ID: 20592159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
